Oxford Immunotec Schedules Third Quarter 2018 Earnings Release and Business Update Conference Call for November 9, 2018

Udgivet den 06-11-2018  |  kl. 22:12  |  

OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced that it plans to release third quarter 2018 financial results prior to market open on Friday, November 9, 2018. Dr. Peter Wrighton-Smith, Chief Executive Officer, Rick Altieri, Chief Financial Officer, and Karen Koski, Vice President, Strategy and Investor Relations will host a conference call to review the Company's third quarter 2018 financial results and provide a business update at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast.

To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 7673307, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately 60 days.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company's T-SPOT®.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company is headquartered near Oxford, U.K. and in Marlborough, MA. Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

CONTACTS:

For Media and Investor Inquiries:
Karen Koski
VP, Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377
kkoski@oxfordimmunotec.com

\Hugin

Udgivet af: NPinvestordk

Mest læste lige nu

Vestas får 50 megawatt-ordre i Sydkorea
Aktier/tendens: Bavarian og Nilfisk kan få genrejsning i positiv start
Aktier/middag: Bavarian Nordic tager revanche i splittet og lettere negativt C25
Bavarian Nordic: Farlig variant af mpox konstateret for første gang i USA
Bavarian får løftet kursmålet til 360 kr. fra 345 kr. af Nordea efter vildt kursfald
 

Seneste nyheder

11:28 Vestas har sikret sig to ordrer i Tyskland på samlet 194 megawatt
11:14 NKT-rival stiger på kapitalmarkedsdag med 2028-målsætninger
10:32 Lundbeck leverer endnu et stærkt vækstkvartal og holder dampen oppe frem mod patentudløb
10:29 Svitzer-chef ser fortsatte prisstigninger på grund af inflationen trods normalisering
10:24 Svitzer-topchef fastholder prognose trods stærke tal for de første ni måneder af 2024
10:00 Svitzer/CEO: Vi fortsat prisstigninger på grund af inflationen
09:47 Siemens Energy sendes i rekord efter løft af mellemlang prognose
09:39 Lundbeck belønnes for nyt stærk kvartal og endnu en opjustering
09:30 Scandinavian Tobacco Groups markedsværdi går op i røg efter regnskab
09:20 Svitzer-topchef fastholder prognose trods stærke tal for de første ni måneder af 2024
09:09 Aktier/åbning: Royal Unibrew, STG og Lundbeck trodser rød åbning efter opjusteringer
08:48 Obligationer/åbning: Renter stiger før inflationtal fra USA
08:26 Svitzer lander et godt tredje kvartal i udskilningsår
08:08 Aktier/tendens: Royal Unibrew, STG og Lundbeck stjæler scenen med opjusteringer
07:58 Råvarer: Oliepriserne bevæger sig op men tynges af dalende efterspørgselsprognoser
07:56 Lundbeck skruer endnu en gang op for forventningerne efter godt tredje kvartal
07:22 Obligationer/tendens: Renter kan stige let før inflationtal fra USA
07:18 Tysk forsikringsselskab slår forventningerne på mere roligt kvartal vejrmæssigt
07:07 Unibrews regnskab vil blive taget godt imod vurderer finanshuset Citi
07:00 Tryg får sat kursmålet op med 5 pct. af amerikansk børshus